186 related articles for article (PubMed ID: 7930204)
1. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes.
Kolodgie FD; Farb A; Carlson GC; Wilson PS; Virmani R
J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion.
Forman MB; Pitarys CJ; Vildibill HD; Lambert TL; Ingram DA; Virmani R; Murray JJ
J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335
[TBL] [Abstract][Full Text] [Related]
3. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
[TBL] [Abstract][Full Text] [Related]
4. Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury.
Forman MB; Ingram DA; Murray JJ
Am Heart J; 1992 Nov; 124(5):1347-57. PubMed ID: 1442506
[TBL] [Abstract][Full Text] [Related]
5. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function.
Schaer GL; Hursey TL; Abrahams SL; Buddemeier K; Ennis B; Rodriguez ER; Hubbell JP; Moy J; Parrillo JE
Circulation; 1994 Dec; 90(6):2964-75. PubMed ID: 7994844
[TBL] [Abstract][Full Text] [Related]
6. Limitation of no reflow injury by blood-free reperfusion with oxygenated perfluorochemical (Fluosol-DA 20%).
Kolodgie FD; Virmani R; Farb A
J Am Coll Cardiol; 1991 Jul; 18(1):215-23. PubMed ID: 2050924
[TBL] [Abstract][Full Text] [Related]
7. Effect of two perfluorocarbon emulsions on reperfusion injury after coronary artery occlusion in rabbits.
Hale SL; Hammerman H; Kloner RA
Basic Res Cardiol; 1995; 90(5):404-9. PubMed ID: 8585862
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent reduction of myocardial infarct size with the perfluorochemical Fluosol-DA.
Rice HE; Virmani R; Hart CL; Kolodgie FD; Farb A
Am Heart J; 1990 Nov; 120(5):1039-46. PubMed ID: 2239656
[TBL] [Abstract][Full Text] [Related]
9. The effect of perfluorochemical fluosol-DA (20%) on myocardial infarct healing in the rabbit.
Virmani R; Osmialowski AF; Kolodgie FD; Forman MB
Am J Cardiovasc Pathol; 1990; 3(1):69-80. PubMed ID: 2331363
[TBL] [Abstract][Full Text] [Related]
10. Beneficial long-term effect of intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model.
Forman MB; Puett DW; Wilson BH; Vaughn WK; Friesinger GC; Virmani R
J Am Coll Cardiol; 1987 May; 9(5):1082-90. PubMed ID: 3571747
[TBL] [Abstract][Full Text] [Related]
11. Fluosol in myocardial reperfusion injury.
Murray JJ; Vitola JV; Schaer GL; Forman MB
J Am Coll Cardiol; 1995 Jun; 25(7):1742-3. PubMed ID: 7759734
[No Abstract] [Full Text] [Related]
12. Effect of perfluorochemical (Fluosol-DA) on infarct morphology in dogs.
Kolodgie FD; Dawson AK; Forman MB; Virmani R
Virchows Arch B Cell Pathol Incl Mol Pathol; 1985; 50(2):119-34. PubMed ID: 2868560
[TBL] [Abstract][Full Text] [Related]
13. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia.
Kolodgie FD; Dawson AK; Roden DM; Forman MB; Virmani R
Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766
[TBL] [Abstract][Full Text] [Related]
14. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion.
Forman MB; Bingham S; Kopelman HA; Wehr C; Sandler MP; Kolodgie F; Vaughn WK; Friesinger GC; Virmani R
Circulation; 1985 May; 71(5):1060-8. PubMed ID: 3986976
[TBL] [Abstract][Full Text] [Related]
15. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
Mizumura T; Nithipatikom K; Gross GJ
Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671
[TBL] [Abstract][Full Text] [Related]
16. Hyperoxemic reperfusion does not increase myocardial infarct size.
Shnier CB; Cason BA; Horton AF; Hickey RF
Am J Physiol; 1991 Apr; 260(4 Pt 2):H1307-12. PubMed ID: 1707244
[TBL] [Abstract][Full Text] [Related]
17. Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction.
Schaer GL; Karas SP; Santoian EC; Gold C; Visner MS; Virmani R
J Am Coll Cardiol; 1990 May; 15(6):1385-93. PubMed ID: 2329241
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group.
Wall TC; Califf RM; Blankenship J; Talley JD; Tannenbaum M; Schwaiger M; Gacioch G; Cohen MD; Sanz M; Leimberger JD
Circulation; 1994 Jul; 90(1):114-20. PubMed ID: 8025985
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury.
Litt MR; Jeremy RW; Weisman HF; Winkelstein JA; Becker LC
Circulation; 1989 Dec; 80(6):1816-27. PubMed ID: 2598440
[TBL] [Abstract][Full Text] [Related]
20. Effects of perfluorocarbon exchange transfusion on reducing myocardial infarct size in a primate model of ischemia-reperfusion injury: a prospective, randomized study.
Premaratne S; Harada RN; Chun P; Suehiro A; McNamara JJ
Surgery; 1995 Jun; 117(6):670-6. PubMed ID: 7778030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
